Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (561-570 of 692) with videos related to

Pageof 70
Sort By:
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
JCO Precision Oncology|August 29, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene AlterationsJose Mauricio Mota, Ethan Barnett, Jones T Nauseef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug developmentGary J Kelloff, John M Hoffman, Bruce Johnson, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
JAMA Oncology|July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical TrialKaren A Autio, Robert Dreicer, Justine Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.
The Prostate|May 10, 2022
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data qualityNiamh M Keegan, Samantha E Vasselman, Ethan S Barnett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris, Chaitanya R Divgi, Neeta Pandit-Taskar, et al.
Pageof 70

Showing results (561-570 of 692) with videos related to

Sort By:
Pageof 70
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
JCO Precision Oncology|August 29, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene AlterationsJose Mauricio Mota, Ethan Barnett, Jones T Nauseef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug developmentGary J Kelloff, John M Hoffman, Bruce Johnson, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
JAMA Oncology|July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical TrialKaren A Autio, Robert Dreicer, Justine Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.
The Prostate|May 10, 2022
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data qualityNiamh M Keegan, Samantha E Vasselman, Ethan S Barnett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris, Chaitanya R Divgi, Neeta Pandit-Taskar, et al.
Pageof 70